Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone

Clifford J. Bailey, Brian D. Green, Peter R. Flatt

Research output: Contribution to journalArticle

Abstract

Type 2 diabetes is typically associated with insulin resistance and dysfunction of insulin-secreting pancreatic beta-cells. Addressing these defects often requires therapy with a combination of differently acting antidiabetic agents. A potential novel combination in development brings together the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin with the thiazolidinedione pioglitazone into a fixed-dose single-tablet combination. The former component acts mainly to increase prandial insulin secretion; the latter improves insulin sensitivity.
Original languageEnglish
Pages (from-to)1017-1025
Number of pages9
JournalExpert Opinion on Investigational Drugs: authoritative analysis of r and d trends
Volume19
Issue number8
DOIs
Publication statusPublished - Aug 2010

Fingerprint

pioglitazone
Insulin-Secreting Cells
Type 2 Diabetes Mellitus
Insulin Resistance
Dipeptidyl-Peptidase IV Inhibitors
Hypoglycemic Agents
Tablets
Meals
Insulin
Therapeutics
Sitagliptin Phosphate

Keywords

  • Animals
  • Clinical Trials as Topic
  • Diabetes Mellitus, Type 2
  • Dipeptidyl-Peptidase IV Inhibitors
  • Drug Therapy, Combination
  • Female
  • Humans
  • Hypoglycemia
  • Hypoglycemic Agents
  • Insulin Resistance
  • Male
  • Pyrazines
  • Thiazolidinediones
  • Triazoles

Cite this

@article{1a1de0ecb5e2462580e0d4a697ad7bfe,
title = "Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone",
abstract = "Type 2 diabetes is typically associated with insulin resistance and dysfunction of insulin-secreting pancreatic beta-cells. Addressing these defects often requires therapy with a combination of differently acting antidiabetic agents. A potential novel combination in development brings together the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin with the thiazolidinedione pioglitazone into a fixed-dose single-tablet combination. The former component acts mainly to increase prandial insulin secretion; the latter improves insulin sensitivity.",
keywords = "Animals, Clinical Trials as Topic, Diabetes Mellitus, Type 2, Dipeptidyl-Peptidase IV Inhibitors, Drug Therapy, Combination, Female, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin Resistance, Male, Pyrazines, Thiazolidinediones, Triazoles",
author = "Bailey, {Clifford J.} and Green, {Brian D.} and Flatt, {Peter R.}",
year = "2010",
month = "8",
doi = "10.1517/13543784.2010.505235",
language = "English",
volume = "19",
pages = "1017--1025",
journal = "Expert Opinion on Investigational Drugs: authoritative analysis of r and d trends",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "8",

}

Fixed-dose combination therapy for type 2 diabetes : sitagliptin plus pioglitazone. / Bailey, Clifford J.; Green, Brian D.; Flatt, Peter R.

In: Expert Opinion on Investigational Drugs: authoritative analysis of r and d trends , Vol. 19, No. 8, 08.2010, p. 1017-1025.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Fixed-dose combination therapy for type 2 diabetes

T2 - sitagliptin plus pioglitazone

AU - Bailey, Clifford J.

AU - Green, Brian D.

AU - Flatt, Peter R.

PY - 2010/8

Y1 - 2010/8

N2 - Type 2 diabetes is typically associated with insulin resistance and dysfunction of insulin-secreting pancreatic beta-cells. Addressing these defects often requires therapy with a combination of differently acting antidiabetic agents. A potential novel combination in development brings together the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin with the thiazolidinedione pioglitazone into a fixed-dose single-tablet combination. The former component acts mainly to increase prandial insulin secretion; the latter improves insulin sensitivity.

AB - Type 2 diabetes is typically associated with insulin resistance and dysfunction of insulin-secreting pancreatic beta-cells. Addressing these defects often requires therapy with a combination of differently acting antidiabetic agents. A potential novel combination in development brings together the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin with the thiazolidinedione pioglitazone into a fixed-dose single-tablet combination. The former component acts mainly to increase prandial insulin secretion; the latter improves insulin sensitivity.

KW - Animals

KW - Clinical Trials as Topic

KW - Diabetes Mellitus, Type 2

KW - Dipeptidyl-Peptidase IV Inhibitors

KW - Drug Therapy, Combination

KW - Female

KW - Humans

KW - Hypoglycemia

KW - Hypoglycemic Agents

KW - Insulin Resistance

KW - Male

KW - Pyrazines

KW - Thiazolidinediones

KW - Triazoles

UR - http://www.scopus.com/inward/record.url?scp=77954713342&partnerID=8YFLogxK

U2 - 10.1517/13543784.2010.505235

DO - 10.1517/13543784.2010.505235

M3 - Article

C2 - 20629618

VL - 19

SP - 1017

EP - 1025

JO - Expert Opinion on Investigational Drugs: authoritative analysis of r and d trends

JF - Expert Opinion on Investigational Drugs: authoritative analysis of r and d trends

SN - 1354-3784

IS - 8

ER -